India Glycols converts ethanol into four product families: Biofuels (ethanol for blending), Potable Spirits (country liquor and IMFL), Performance Chemicals (bio-based amines and other specialty molecules), and Ennature Biopharma (nutraceuticals). In the quarter ended September 2025, Biofuels posted net revenue of INR 423 crore, up 63% year on year, but an EBIT margin of only 6.9%; Potable Spirits delivered INR 338 crore with a 21.4% EBIT margin, up from 20.5% a year earlier; Chemicals (excluding the JV) saw revenue fall to INR 288 crore but maintained flat EBIT; Ennature reported INR 43 crore with margins under pressure. The company holds leadership in Country Liquor and IMFL in Uttar Pradesh and Uttarakhand, and claims to be the first firm globally to produce bio-based amines, now selling to L'Oreal. Overall EBITDA margin expanded from 12.4% to 14.6% in Q2 FY26, but the profit mix is uneven: high-margin spirits and specialty chemicals offset thin ethanol conversion.
The economics persist because of three distinct barriers. First, captive high-quality Extra Neutral Alcohol from its Kashipur plant underpins a 15-year manufacturing contract for Bacardi, proving quality consistency that competitors cannot easily replicate. Second, the exclusive long-term rights to distribute and profit-share Amrut single malts in select North Indian markets give India Glycols access to a premium brand without advertising spend, creating switching costs for distributors. Third, performance chemicals involve customer qualification cycles with BASF, Dow, Newpark, and L'Oreal; bio-based amines are a first-mover product where substitution to cheaper petrochemical alternatives is limited by sustainability preferences. In contrast, the Biofuels segment is a scale game: with industry-wide excess ethanol capacity and blending plateaued at 20%, margins there remain in single digits and are tied to government policy.
The inflection is a deliberate shift toward higher-margin businesses while deleveraging. Management raised INR 467 crore via preferential allotment to promoters and prepaid INR 582 crore of debt by early 2026 (INR 467 crore from that allotment plus INR 116 crore from accruals), with another INR 100-150 crore prepayment planned in April 2026; this will cut annual interest cost by INR 60-70 crore. In parallel, performance chemicals are targeted to double revenue and contribution in FY26, backed by a pipeline of over 30 new products across crop protection, personal care, carbon smart materials, oilfield, and flavour/fragrance. Potable spirits are expanding into Kerala (7 brands approved), Andhra Pradesh, Rajasthan, and a pan-India CSD rollout across 34 depots for Zumba Lemoni Citrus Rum and Soulmate Whisky. By FY27, management guides to 22% EBIT margin, achieved through premiumisation and ethanol cost advantages. Eighteen to twenty-four months out, the company should have a substantially lower debt load (term debt near INR 1,100 crore at end-FY26, falling further), a scaled performance chemicals business with bio-based amines selling to multiple customers, and a potable spirits portfolio with national distribution and a richer premium mix.
Management has a mixed but improving walk-talk record. On the August 2025 call, they promised a consolidation year with INR 40-50 crore maintenance capex and INR 300 crore debt reduction; by the February 2026 call, they had prepaid INR 582 crore, beating that commitment. They also guided to low-double-digit Chemicals EBIT margin and delivered 12.8% in Q3FY26, up from 8.5% a year earlier. However, Ennature's recovery has slipped: management expected improvement in Q4FY26 but its margin was still 4.1% in the latest quarter versus 20%+ two years ago, so the turnaround is pushed forward. Capital allocation is conservative: major capex is deferred until after the planned demerger, and the preferential allotment was used entirely for debt reduction. The FY27 EBIT margin guidance of 22% is a clear quantitative commitment that will frame the next two years.
The quantified earnings path: interest savings of INR 60-70 crore annually, performance chemicals revenue doubling from current levels, Potable Spirits EBIT margin sustaining 21-22%, and Ennature recovering to double-digit margins would together lift consolidated EBITDA margin from 14.6% to the guided 22% by FY27. For that to hold, the government must maintain or raise the ethanol blending mandate (currently 20%, with a review to 25-27%), crude oil prices must stay high enough to keep bio-based chemicals competitive, and Ennature must secure the regulatory approvals it seeks in Europe and the US. The single most important watchpoint is Ennature: if its margin does not move from the 4.1% level by Q4FY26, the 22% EBIT margin target is at risk. The tension between the delivered Chemicals beat and the delayed Ennature recovery is operational, not structural, and resolves only when the nutraceutical business regains its historical margin profile.
companyname: India Glycols Limited ticker: INDIAGLYCO sector: Bio-based chemicals, potable spirits, bio-fuels (ethanol), and nutraceuticals/APIs India Glycols Limited (CIN: L24111UR1983PLC009097), incorporated in 1983, is a diversified manufacturer built around one core capability: converting renewable feedstocks - molasses, grain, and sugarcane-based ethanol - into chemicals, spirits, and bio-fuels. The company operates three manufacturing sites: Kashipur (Uttarakhand), Gorakhpur (Uttar Prades...
Read the full report →margin expansion, regulatory approval, geographic expansion, debt reduction
FY27 EBIT margin guided at 22% driven by premiumization and ethanol cost advantages
Guidance no_datamixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for India Glycols Limited and 4,900+ companies.
5-day free pass. No card required.